ImmunityBio, Inc. logo

ImmunityBio, Inc.

NASDAQ:IBRX

Overview | Financials
Company Name ImmunityBio, Inc.
Symbol IBRX
Currency USD
Price 3.19
Market Cap 2,329,226,350
Dividend Yield 0%
52-week-range 2.28 - 10.53
Industry Biotechnology
Sector Healthcare
CEO Mr. Richard Gerald Adcock
Website https://immunitybio.com

An error occurred while fetching data.

About ImmunityBio, Inc.

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in

Related Stocks

Krystal Biotech, Inc. logo

Krystal Biotech, Inc.

KRYS

161.3 USD

Establishment Labs Holdings Inc. logo

Establishment Labs Holdings Inc.

ESTA

30.725 USD

Addus HomeCare Corporation logo

Addus HomeCare Corporation

ADUS

123.02 USD

Travere Therapeutics, Inc. logo

Travere Therapeutics, Inc.

TVTX

21.1 USD

Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc.

XENE

39.98 USD

Ligand Pharmaceuticals Incorporated logo

Ligand Pharmaceuticals Incorporated

LGND

117.26 USD

Dynavax Technologies Corporation logo

Dynavax Technologies Corporation

DVAX

13 USD

ModivCare Inc. logo

ModivCare Inc.

MODV

4.8 USD

Supernus Pharmaceuticals, Inc. logo

Supernus Pharmaceuticals, Inc.

SUPN

40 USD

Financials

Numbers are in millions USD

Numbers are in millions USD